BDC Commits $150M to Early-Stage Life Sciences Venture Fund
Event summary
- BDC launched a $150 million Life Sciences Venture Fund on April 9, 2026, targeting seed and Series A companies in therapeutics and medical technologies.
- The fund aims to address financing gaps in early-stage life sciences, a sector contributing $18.3 billion annually to Canada’s economy.
- Parimal Nathwani, with over 20 years of life sciences experience, appointed as Managing Partner to lead the fund.
The big picture
BDC’s $150 million fund targets a critical gap in early-stage life sciences financing, a sector where Canada has strong innovation but struggles with long development cycles and scientific validation. The move aligns with broader efforts to bolster economic sovereignty and retain scientific talent domestically. With life sciences contributing 0.8% of Canada’s GDP, this fund could accelerate the commercialization of therapeutic and medical technology innovations.
What we're watching
- Fund Deployment
- How quickly BDC deploys the $150 million and the types of companies it backs will signal its strategic focus.
- Competitive Positioning
- Whether this fund can reduce Canada’s reliance on foreign investment in life sciences.
- Economic Impact
- The pace at which funded companies translate research into globally competitive businesses.
Related topics